CNBC’s David Faber and Carl Icahn, chairman, Icahn Enterprises LP (NASDAQ:IEP), discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman’s recent efforts to partner with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and acquire Allergan, Inc. (NYSE:AGN).
Carl Icahn: We see things boards don’t
The first London Value Investor Conference was held in April 2012 and it has since grown to become the largest gathering of Value Investors in Europe, bringing together some of the best investors every year. At this year’s conference, held on May 19th, Simon Brewer, the former CIO of Morgan Stanley and Senior Adviser to Read More